ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,241.26
0.86%
Dow Jones
39,308.00
-0.06%
Gold vs US Dollar
2,357.305
-0.04%
Brent Oil
87.33
0.48%
Bitcoin
58,084.93
-3.45%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Intellia Therapeutics Inc (NTLA) Share Price

NTLA Intellia Therapeutics Inc

22.95
0.80 (3.61%)
03 Jul 2024 - Closed
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Intellia Therapeutics Inc NASDAQ:NTLA NASDAQ Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   0.80 3.61 22.95 22.78 23.32 23.15 22.15 22.42 843,311 21:00:00   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 In Vitro,in Vivo Diagnostics 36.28M -481.19M -4.9877 -4.60 2.21B
 Type  Size  Price  Time  Units 
 9 19 22.98 20:49:27 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore NTLA News
02/07/202417:53PRNUSKuehn Law Encourages Investors of Intellia Therapeutics, Inc. to Contact Law Firm
26/06/202412:30GLOBEIntellia Therapeutics Announces CFO Transition
25/06/202420:30GLOBEIntellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform
17/06/202412:30GLOBEIntellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024
14/06/202421:24EDGAR2Form 8-K - Current report
14/06/202421:21EDGAR2Form 4 - Statement of changes in beneficial ownership of securities
14/06/202421:20EDGAR2Form 4 - Statement of changes in beneficial ownership of securities
Period
Draw mode
Data Downloads for NTLA

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Intellia Therapeutics Inc Articles